Findings from the COLCORONA trial suggest that the anti-inflammatory drug colchicine improved COVID-19 outcomes among patients with relatively mild disease.

The drug was found to diminish the risk of death or hospitalizations by 21% in comparison with placebo. The results reached statistical significance. A significant effect was evident in the 4,159 patients out of 4,488 with COVID-19 confirmed by a positive PCR test. There were 25% fewer hospitalizations, 50% less requirement of mechanical ventilation, and 44% fewer deaths. According to principal investigator Jean-Claude Tardif, the findings point to the efficacy of treatment with colchicine in preventing cytokine storm and decreasing the complications tied to COVID-19… (Medpage Today)